Editas Medicine
EDIT
318 hedge funds and large institutions have $2.17B invested in Editas Medicine in 2021 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 98 increasing their positions, 97 reducing their positions, and 48 closing their positions.
19% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 48
2% more funds holding
Funds holding: 313 → 318 (+5)
1% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 97
0.17% less ownership
Funds ownership: 76.9% → 76.73% (-0.17%)
27% less capital invested
Capital invested by funds: $2.96B → $2.17B (-$788M)
48% less call options, than puts
Call options by funds: $95.7M | Put options by funds: $183M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$59M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$38.8M |
| 3 |
Goldman Sachs
New York
|
+$32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$29.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$48.4M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$33.6M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
-$33.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$20.6M |
| 5 |
Two Sigma Advisers
New York
|
-$13.9M |
EDIT Hedge Fund Activity: Q3 2021 in Review
318 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2021, worth a combined $2.17B — down 27% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new EDIT positions and 48 closed out — a net gain of 9 holders — while 98 added to existing stakes and 97 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $59M. The largest seller was ARK Investment Management, cutting an estimated $48.4M.
- 318 institutional investors held Editas Medicine (EDIT) as of Q3 2021, up from 313 in Q2 2021.
- Funds reported $2.17B of Editas Medicine stock for Q3 2021, down 27% quarter-over-quarter.
- 57 funds opened new Editas Medicine positions in Q3 2021 and 48 closed out, a net change of +9 holders.
- The largest Editas Medicine buyer in Q3 2021 was Victory Capital Management, an estimated $59M added.
- The largest Editas Medicine seller in Q3 2021 was ARK Investment Management, an estimated $48.4M sold.
Based on aggregated 13F filings for Q3 2021.